MX2023010840A - Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados. - Google Patents

Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados.

Info

Publication number
MX2023010840A
MX2023010840A MX2023010840A MX2023010840A MX2023010840A MX 2023010840 A MX2023010840 A MX 2023010840A MX 2023010840 A MX2023010840 A MX 2023010840A MX 2023010840 A MX2023010840 A MX 2023010840A MX 2023010840 A MX2023010840 A MX 2023010840A
Authority
MX
Mexico
Prior art keywords
methods
related compositions
activatable
cytokine
constructs
Prior art date
Application number
MX2023010840A
Other languages
English (en)
Inventor
Alexey Yevgenyevich Berezhnoy
Sayantan Mitra
Nicole G Lapuyade
Hikmat Haizar Assi
Madan M Paidhungat
Dylan L Daniel
Walter A Bogdanoff
Na Cai
Scolan Erwan Le
Hsin Wang
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of MX2023010840A publication Critical patent/MX2023010840A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan en el presente documento construcciones de citocina activables que incluyen: (a) una primera construcción monomérica que comprende una primera máscara peptídica (PM1), un tercer resto escindible (CM3), una primera proteína de citocina madura (CP1), un primer resto escindible (CM1), y un primer dominio de dimerización (DD1), en donde la CM1 se sitúa entre la CP1 y la DD1, y la CM3 se sitúa entre la PM1 y la CP1; y (b) una segunda construcción monomérica que comprende una segunda proteína de citocina madura (CP2), un segundo resto escindible (CM2), y un segundo dominio de dimerización (DD2), en donde el CM2 está situado entre la CP2 y el DD2, en donde: el DD1 y el DD2 se unen entre sí; y donde la ACC se caracteriza por una reducción de al menos una actividad de la CP1 y/o CP2 en comparación con un nivel de control de la al menos una actividad de la CP1 y/o CP2.
MX2023010840A 2021-03-16 2022-03-16 Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados. MX2023010840A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163161913P 2021-03-16 2021-03-16
US202163164827P 2021-03-23 2021-03-23
US202163254748P 2021-10-12 2021-10-12
US202163276893P 2021-11-08 2021-11-08
PCT/US2022/020492 WO2022197764A2 (en) 2021-03-16 2022-03-16 Masked activatable cytokine constructs and related compositions and methods

Publications (1)

Publication Number Publication Date
MX2023010840A true MX2023010840A (es) 2023-10-26

Family

ID=81389111

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010840A MX2023010840A (es) 2021-03-16 2022-03-16 Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados.

Country Status (11)

Country Link
US (2) US11667687B2 (es)
EP (1) EP4308594A2 (es)
JP (1) JP2024511387A (es)
KR (1) KR20230157448A (es)
AU (1) AU2022237504A1 (es)
BR (1) BR112023018735A2 (es)
CA (1) CA3211924A1 (es)
IL (1) IL305716A (es)
MX (1) MX2023010840A (es)
TW (1) TW202304958A (es)
WO (1) WO2022197764A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202334185A (zh) * 2021-10-08 2023-09-01 美商Ｃｙｔｏｍｘ生物製藥公司 可經活化之細胞介素構築體和組合方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO2001091798A2 (en) 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
RU2272644C2 (ru) 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
ES2368387T5 (es) 2000-10-09 2019-03-07 Cytomx Therapeutics Inc Anticuerpos terapéuticos y que inducen tolerancia
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US6942853B2 (en) 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
US20060024272A1 (en) 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
EP1899368A2 (en) 2005-05-26 2008-03-19 Schering Corporation Interferon-igg fusion
WO2007105027A1 (en) 2006-03-10 2007-09-20 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
US20100297081A1 (en) 2007-12-18 2010-11-25 Huang Yanshan Pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
WO2011123683A2 (en) 2010-04-02 2011-10-06 University Of Rochester Protease activated cytokines
CA2814595C (en) 2010-12-03 2020-06-16 Adamed Sp. Z O.O. Anticancer fusion protein
WO2012099886A1 (en) 2011-01-18 2012-07-26 Bioniz, Llc Compositions and mehthods for modulating gamma-c-cytokine activity
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
EP3049111A2 (en) 2013-09-25 2016-08-03 Cytomx Therapeutics Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
EP4176896A1 (en) 2014-01-31 2023-05-10 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
GB201411506D0 (en) 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
MX2017005148A (es) 2014-11-06 2017-08-08 Hoffmann La Roche Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
JP2019518786A (ja) 2016-05-06 2019-07-04 牧林 王 インターロイキンの組み合せ及びその使用
KR102649972B1 (ko) 2016-10-14 2024-03-22 젠코어 인코포레이티드 IL15/IL15Rα 이종이량체 Fc-융합 단백질
CN111050803A (zh) 2017-06-20 2020-04-21 德克萨斯大学系统董事会 用于治疗癌症的干扰素前药
KR20200064096A (ko) 2017-10-14 2020-06-05 싸이톰스 테라퓨틱스, 인크. 항체, 활성화 가능한 항체, 이중특이적 항체 및 이중특이적 활성화 가능한 항체 및 이들의 사용 방법
JP7404252B2 (ja) 2017-11-08 2023-12-25 ヤフェイ シャンハイ バイオロジー メディスン サイエンス アンド テクノロジー カンパニー リミテッド 生体分子のコンジュゲートおよびその使用
TWI800552B (zh) 2017-11-10 2023-05-01 新加坡科技研究局 介白素2受體β(IL2Rβ)/共同γ鏈抗體
JP7386161B2 (ja) 2017-12-19 2023-11-24 ブレイズ バイオサイエンス， インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
WO2020113403A1 (en) 2018-12-04 2020-06-11 Beijing Percans Oncology Co. Ltd. Cytokine fusion proteins
WO2019173832A2 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
WO2019222295A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2019230868A1 (ja) 2018-05-30 2019-12-05 中外製薬株式会社 単ドメイン抗体含有リガンド結合分子
CA3103023A1 (en) 2018-06-21 2019-12-26 Tgw Logistics Group Gmbh Storage and order-picking system and method for picking ordered articles
WO2019246392A1 (en) 2018-06-22 2019-12-26 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CN112867503A (zh) 2018-08-24 2021-05-28 希望之城 掩蔽的细胞因子缀合物
MX2021003543A (es) 2018-09-27 2021-06-23 Xilio Dev Inc Polipeptidos de citocinas enmascaradas.
WO2020065096A1 (en) 2018-09-28 2020-04-02 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
WO2020086758A1 (en) 2018-10-23 2020-04-30 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
CA3120327A1 (en) 2018-12-06 2020-06-11 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
US20230045048A1 (en) 2018-12-14 2023-02-09 Proviva Therapeutics (Hong Kong) Limited Il-15 compositions and methods of use thereof
JP2022529943A (ja) * 2019-04-15 2022-06-27 クウィクセル セラピューティクス リミテッド ライアビリティ カンパニー がんの処置における使用のための、標的指向性のマスクされたｉ型インターフェロン（ｉｆｎａおよびｉｆｎｂ）と腫瘍抗原に対する抗体とを含む融合タンパク質組成物
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
KR20220012256A (ko) 2019-05-24 2022-02-03 프로비바 테라퓨틱스 (홍콩) 리미티드 Il-2 조성물 및 이의 사용 방법
US20220315909A1 (en) 2019-06-05 2022-10-06 Chugai Seiyaku Kabushiki Kaisha Protease substrate, and polypeptide including protease cleavage sequence
AU2020291012A1 (en) 2019-06-12 2021-12-16 AskGene Pharma, Inc. Novel IL-15 prodrugs and methods of use thereof
EP3997115A4 (en) 2019-07-12 2023-11-22 Proviva Therapeutics (Hong Kong) Limited IL-2 COMPOSITIONS AND METHODS OF USE THEREOF
EP4004026A4 (en) 2019-07-25 2023-11-15 Trutino Biosciences Inc. IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER
AU2020316002A1 (en) 2019-07-25 2022-03-03 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
AU2020329216A1 (en) 2019-08-12 2022-02-24 AskGene Pharma, Inc. IL-2 fusion proteins that preferentially bind ILl-2ralpha
EP4017594A1 (en) 2019-08-21 2022-06-29 Askgene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
US20220356221A1 (en) 2019-09-28 2022-11-10 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
CN115315434A (zh) 2019-12-05 2022-11-08 免疫靶向有限公司 白细胞介素15融合蛋白和前药及其组合物和方法
MX2022007202A (es) 2019-12-13 2022-10-07 Cugene Inc Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
JP2023510115A (ja) 2019-12-20 2023-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 新規ｉｌ２アゴニストおよびそれらの使用方法
BR112022013993A2 (pt) 2020-01-15 2022-10-11 Trutino Biosciences Inc Profármacos de citocina compreendendo um ligante clivável
AU2021240872A1 (en) 2020-03-23 2022-11-17 Zymeworks Bc Inc. Masked IL12 fusion proteins and methods of use thereof
US20230226202A1 (en) 2020-03-30 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Il-2/il15 compositions and methods of use thereof
CA3172658A1 (en) 2020-04-01 2021-10-07 Raphael Rozenfeld Masked il-15 cytokines and their cleavage products
CA3172641A1 (en) * 2020-04-01 2021-10-07 Xilio Development, Inc. Masked il-12 cytokines and their cleavage products
MX2022012311A (es) 2020-04-01 2023-01-05 Xilio Dev Inc Citocinas il-2 enmascaradas y sus productos de escisión.
MX2022012592A (es) 2020-04-10 2022-12-07 Cytomx Therapeutics Inc Construcciones de citocinas activables y composiciones y metodos relacionados.
EP4143220A4 (en) 2020-04-30 2024-05-29 Immune Targeting Inc. COMPOSITION OF ACTIVATABLE IL2 AND METHODS OF USE
AU2021276337A1 (en) 2020-05-19 2022-12-22 Werewolf Therapeutics, Inc. Activatable IL-12 polypeptides and methods of use thereof

Also Published As

Publication number Publication date
US11667687B2 (en) 2023-06-06
TW202304958A (zh) 2023-02-01
WO2022197764A2 (en) 2022-09-22
JP2024511387A (ja) 2024-03-13
EP4308594A2 (en) 2024-01-24
BR112023018735A2 (pt) 2023-11-28
IL305716A (en) 2023-11-01
AU2022237504A1 (en) 2023-10-05
KR20230157448A (ko) 2023-11-16
WO2022197764A3 (en) 2022-11-03
CA3211924A1 (en) 2022-09-22
US20220306717A1 (en) 2022-09-29
US20240124546A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
MX2022012592A (es) Construcciones de citocinas activables y composiciones y metodos relacionados.
MX2023010840A (es) Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados.
TW200726046A (en) Switched converter with variable peak current and variable off-time control
GB2378591A (en) RF power amplifier and methods for improving the efficiency thereof
WO2003047685A3 (en) Control of arbitrary waveforms for constant delivered energy
CN105932970A (zh) 包络跟踪的Doherty功率放大器
MX2022002686A (es) Cianopirrolidinas sustituidas con actividad como inhibidores de peptidasa 30 especifica de ubiquitina (usp30).
BR112022022401A2 (pt) Terapia de combinação tripla para aumentar o extermínio de células cancerígenas em cânceres com baixa imunogenicidade
WO2023060156A3 (en) Activatable cytokine constructs and related compositions and methods
MX2022010542A (es) Composiciones y metodos para reducir la expresion de citocinas.
ATE383084T1 (de) Sosse auf käsebasis
CN102185564A (zh) 功率放大装置及功放电路
BR0208694A (pt) Uso de inibidores de cox-2 seletivos para tratamento de incontinência urinária
ATE519496T1 (de) Therapeutische anwendung von g-csf
MX2022012578A (es) N-cianopirrolidinas con actividad como inhibidores de usp30.
CN201113924Y (zh) 带直流偏置的二极管双平衡混频器
GB672865A (en) Improvements in and relating to radio ranging systems
CN202288392U (zh) 解剖型多普勒气囊止血带
AR125090A1 (es) Construcciones de citoquinas activables enmascaradas y composiciones y métodos relacionados
CN201499137U (zh) 功率放大器
Hsia et al. Effect of maximum power supply voltage on envelope tracking power amplifiers using GaN HEMTs
CN205545167U (zh) 双模功率放大器
WO2020022627A8 (ko) 소음순 피부 치료용 피부연고
SG52727A1 (en) Lysozyme dimer and compositions containing the same
WO2022192439A8 (en) Improving immune cell function